Susceptibility of liver proliferative lesions in heterozygous p53 deficient CBA mice to various carcinogens

Journal of Veterinary Medical Science

Volumn 64, Issue 7, 2002, Pages 551-556

  Uehara, Takeki ^a   Kashida, Yoko ^a   Watanabe, Takao ^a   Yasuhara, Kazuo ^b   Onodera, Hiroshi ^b   Hirose, Masao ^b   Mitsumori, Kimitoshi ^a,b  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Di(2 ethylhexyl) phthalate; Dimethylnitrosamine; Flumequine; P53 (+ ) CBA mouse; Phenolphthalein

Indexed keywords

ANIMALIA;

CARCINOGEN; PROTEIN P53;

ANIMAL; ARTICLE; CBA MOUSE; CHEMICALLY INDUCED DISORDER; GENE DELETION; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; LIVER TUMOR; MALE; MOUSE; MOUSE MUTANT; PATHOLOGY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENS; GENE DELETION; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; INCIDENCE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED CBA; MICE, KNOCKOUT; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036636289     PISSN: 09167250     EISSN: None     Source Type: Journal    
DOI: 10.1292/jvms.64.551     Document Type: Article

References (21)

1. Armato, U., Wu, J., Menegazzi, M., Menapace, L., Ribecco, M., Testolin, L., Carcereri De Prati, A. and Suzuki, H. 1993. The in utero initiation with DMN alters the complement of cytosolic glutathione S-transferases and the phenobarbital-induced expression of c-jun and c-myc oncogenes in primary neonatal rat hepatocytes. Cytotechnology (Suppl. 1): S18-20.
2. Ashby, J., Brady, A., Elcombe, C. R., Elliott, B. M., Ishmael, J., Odum, J., Tugwood, J. D., Kettle, S. and Purchase, I. F. 1994. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. (Suppl. 2): S1-117.
3. Dass, S.B., Bucci, T.J., Heflich, R.H. and Casciano, D.A. 1999. Evaluation of the transgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. Cancer Letters 143: 81-85.
4. Engelse, L.D., Hollander, C. F. and Misdorp, W. 1974. A sex-dependent difference in the type of tumours induced by dimethylnitrosamine in the livers of C3Hf mice. Eur. J. Cancer 10: 129-135.
5. Donehower, L. A. and Bradley, A. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155: 181-205.
6. Dunnick, J. K. and Hailey, J. R. 1996. Phenolphthalein exposure causes multiple carcinogenic effects in experimental model systems. Cancer Res. 56: 4922-4926.
7. Dunnick, J. K., Hardisty, J. F., Herbert, R. A., Seely, J. C., Furedi-Machacek, E. M., Foley, J. F., Lacks, G. D., Stasiewicz, S. and French, J. E. 1997. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Toxicol. Pathol. 25: 533-540.
8. Frei, J. V. 1970. Toxicity, tissue changes, and tumor induction in inbred Swiss mice by methylnitrosamine and -amide compounds. Cancer Res. 30: 11-17.
9. Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A. and Donehower, L. A. 1993. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5: 225-229.
10. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. 1991. p53 mutations in human cancers. Science 253: 49-53.
11. Kemp, C. J. 1995. Hepatocarcinogenesis in p53-deficient mice. Mol. Carcinogenesis 12: 132-136.
12. 1 mice. J. Toxicol. Environ. Health. 10: 797-815.
13. Moody, D. E. and Reddy, J. K. 1978. Hepatic peroxisome (microbody) proliferation in rats fed plasticizers and related compounds. Toxicol. Appl. Pharmacol. 45: 497-504.
14. National Toxicology Program (NTP). 1996. Toxicology and carcinogenesis studies of phenolphthalein in F344/N rats and B6C3F1 mice (feed studies). NTP Technical Report No. 465, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda.
15. Onodera, H., Mitsumori, K., Takagi, H., Yasuhara, K., Koujitani, T., Tamura, T. and Hirose, M. Susceptibility of liver proliferative lesions in heterozygous p53 deficient CBA mice treated with phenobarbital after initiation of dimethylnitrosamine. J. Toxicol. Pathol. (in press)
16. Reddy, J. K. and Lalwai, N. D. 1983. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12: 1-58.
17. Takizawa, T., Mitsumori, K., Takagi, H., Onodera, H., Yasuhara, K., Tamura, T. and Hirose, M. 2001. Modifying effects of flumequine on dimethylnitrosamine-induced hepatocarcinogenesis in heterozygous p53 deficient CBA mice. J. Toxicol. Pathol. 14: 135-143.
18. Tennant, R. W., Spalding, J. and French, J. E. 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res. 365: 119-127.
19. Tsukada, T., Tomooka, Y., Takai, S., Ueda, Y., Nishikawa, S., Yagi, T., Tokunaga, T., Takeda, N., Suda, Y., Abe, S., Matsuo, I., Ikawa, Y. and Aizawa, S. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8: 3313-3322.
20. WHO. 1997. Toxicological evaluation of certain veterinary drugs residues in food. The forty-eighth meeting of the joint FAO/WHO expert committee on food additives (JECFA), WHO Food Additives Series 39: 63-75.
21. Yoshida, M., Miyajima, K., Shiraki, K., Ando, J., Kudoh K., Nakae, D., Takahashi, M. and Maekawa, A. 1999. Hepatotoxicity and consequently increased cell proliferation are associated with flumequine hepatocarcinogenesis in mice. Cancer Letters 141: 99-107.